UPDATE: Morgan Stanley Maintains Underweight On Altria, Lowers Target To $44 Due To Firm's 'outlook for accelerated cigarette industry volume declines, growing risk to cigarette net pricing, a deceleration in EPS growth to LSD, and FDA risk'